论文部分内容阅读
目的:分析人乳头瘤病毒脱氧核糖核酸(HPV-DNA)的检测与分型诊断在宫颈癌筛查中的应用价值。方法:选择2013年1月—2014年12月本院进行宫颈癌筛查的高危患者662例作为观察对象,所有患者均应用薄层液基细胞学检验(TCT)及HPV-DNA检验。以宫颈组织病理活检结果作为依据进行对比,观察两组的筛查结果差异。结果:宫颈组织活检结果为阳性的患者282例,阳性比例为42.60%;TCT检查结果为:阳性患者有209例,阳性率达到31.57%;HPVDNA检查结果提检出阳性患者241例,阳性率为38.75%,症状表现越严重,HPV-DNA检查阳性率就越高。而联合TCT与HPV-DNA检查的阳性率为42.30%,特异性高,与病理检查结果接近。联合TCT与HPV-DNA检查阳性率高于单独TCT检验结果,差异具有统计学意义(P<0.05)。结论:HPV-DNA的检测与分型诊断在宫颈癌筛查中具有较高的应用价值,加强对高危人员的筛查,对于帮助判断宫颈病变的发展趋势、合理处理癌前病变、阻断疾病的发展具有关键作用。
Objective: To analyze the diagnostic value of HPV-DNA in the diagnosis of cervical cancer. METHODS: A total of 662 high-risk patients undergoing cervical cancer screening in our hospital from January 2013 to December 2014 were selected as the observation subjects. All patients were examined by TLCT and HPV-DNA. Cervical histopathology biopsy results as a basis for comparison, to observe the difference between the two groups of screening results. Results: The positive rate of cervical biopsy was 282 (42.60%). The positive rate of TCT was 209 (positive rate was 31.57%). The positive rate of HPVDNA was 241 (positive rate was 38.75%, the more severe symptoms, the higher the positive rate of HPV-DNA test. The combined detection of TCT and HPV-DNA positive rate was 42.30%, high specificity, and the results of pathological examination close. The positive rate of combined TCT and HPV-DNA test was higher than that of TCT test alone, the difference was statistically significant (P <0.05). Conclusion: The detection and classification of HPV-DNA in cervical cancer screening has a high value, to strengthen the screening of high-risk personnel, to help determine the development trend of cervical lesions, rational treatment of precancerous lesions, blocking the disease The development of a key role.